Cerulean Pharma has a new chief executive
Cerulean Pharma Inc. said that Oliver S. Fetzer has been named as president and chief executive.
Fetzer, who has also been elected to the company's board of directors, will succeed Alan L. Crane, who has been named chairman of the board, Cerulean Pharma said. Most recently, Fetzer was senior vice president of corporate development and research and development at Cubist Pharmaceuticals, the company said.
Headquartered in Cambridge, Cerulean Pharma is a privately-held biopharmaceutical company that focuses on the development of novel, nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune, and inflammatory diseases.
To read the company's press release, please click here.
(By Chris Reidy, Globe staff)